Anocca

Anocca, founded in 2014 and headquartered in Sweden, is making significant strides in the Biotechnology and Health Care industries with its pioneering approach to Engineered Immunity. The company is a fully integrated biopharmaceutical entity that focuses on developing T-cell receptor-engineered T cell (TCR-T) therapies, aiming to revolutionize the treatment of solid tumors, infectious, and autoimmune diseases.

Anocca's unique discovery engine employs programmable human cells to both recreate and manipulate T cell immunity, optimizing the scaling of TCR-T cell therapy development. Their proprietary AnoccaOS software complements their advanced R&D infrastructure, allowing for the systematic personalization of treatments across broad patient demographics. Significantly, all therapeutic TCRs are novel and developed using non-viral gene editing technology at their Swedish facilities.

In a recent Venture Round investment dated 31 May 2023, Anocca secured kr400.00M from investors including Nidoco AB, Swedbank Robur, Swedish pension fund AMF, Michano AB, Mellby Gård AB, and Ramsbury Invest AB. This investment highlights growing confidence in their innovative capabilities and the potential to reshape the future of healthcare solutions.